TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03496324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nurofen for Children®
Description: Nurofen for Children® 400 mg/10 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nurofen for Children®
Description: Nurofen for Children® 400 mg/10 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Algifor® Junior
Description: Algifor® Junior 400 mg/20 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Algifor® Junior
Description: Algifor® Junior 400 mg/20 ml
Study: NCT02514408

Intervention type: PROCEDURE
Intervention: Catheter Management
Description: Insertion of venous catheter under ultrasound guidance

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Collection of blood samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01145495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT00024167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: 20 mg/m2 IV, day 1 on Weeks 1, 3, 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: 20 mg/m2 IV, day 1 on Weeks 1, 3, 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: 20 mg/m2 IV, day 1 on Weeks 1, 3, 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate sodium
Description: 140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 400 mg orally (po) 3 x day, Days 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally 2 x daily, weeks 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Strontium chloride Sr 89
Description: One dose (4 mCi total dose) IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.
Study: NCT04597957

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Rx Intervention group
Description: Fresh Rx Intervention participants will be able to fill their prescription at the FQHC based Farmers Market for fresh produce up to eight times during the 15-week Fresh Rx program. The provided debit cards will be loaded with the $10 stipend at each visit. At each market session, cooking demonstrations will take place that reinforce healthy food options and how to prepare foods that were available at the Mercado.~All control group participants will be given flyers describing all the health and wellness programs at the FQHC including the Mercado. Control group participants will receive a $10 gift card to a national brand pharmacy (no fresh produce available). The enrollment time for the control group will overlap with the Fresh Rx group. After a 3-month time period, the control group will follow up and be given a $20 gift card to the same national brand pharmacy.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresh Rx Intervention group
Description: Fresh Rx Intervention participants will be able to fill their prescription at the FQHC based Farmers Market for fresh produce up to eight times during the 15-week Fresh Rx program. The provided debit cards will be loaded with the $10 stipend at each visit. At each market session, cooking demonstrations will take place that reinforce healthy food options and how to prepare foods that were available at the Mercado.~All control group participants will be given flyers describing all the health and wellness programs at the FQHC including the Mercado. Control group participants will receive a $10 gift card to a national brand pharmacy (no fresh produce available). The enrollment time for the control group will overlap with the Fresh Rx group. After a 3-month time period, the control group will follow up and be given a $20 gift card to the same national brand pharmacy.
Study: NCT00850850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: physostigmine
Description: 1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic sodium chloride solution
Description: Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.
Study: NCT03262792

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Andrographis Paniculata
Description: Andrographis Paniculata 150 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Andrographis Paniculata
Description: Andrographis Paniculata 300 mg
Study: NCT03122496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: SBRT at 9Gy x 3 per standard of care given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab
Study: NCT01614821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: Taken orally, once daily in the morning
Study: NCT04608513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470
Description: Soft capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470
Description: Soft capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470
Description: Soft capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470
Description: Soft capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470
Description: Soft capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470
Description: Soft capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft capsules for oral administration
Study: NCT02766023

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulation applied vaginally, daily x 5 days then twice weekly x 10 weeks.
Study: NCT03692624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Heart Rate Variability Biofeedback
Study: NCT02941601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV
Study: NCT02764164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention Active tDCS
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered directly to the brain area of interest via small electrodes. Placed over the temporoparietal junction to suppress auditory hallucinations.
Study: NCT04156217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-TCR-T cells
Description: EBV-TCR-T cells are prepared via lentiviral infection. patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
Study: NCT04537273

Intervention type: OTHER
Intervention: Descriptive and analytical
Study: NCT02340728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERCP with SEMS plus radiofrequency ablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with SEMS alone (standard of care)
Study: NCT00551551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with physiotherapist
Description: 8 sessions of 20-30 minutes each between 24 and 36 weeks of gestation with a physiotherapist or midwife

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written information about kegel exercises
Description: Information about pelvic floor disorders prevention with personal pelvic floor exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written information about kegel exercises
Description: Information about pelvic floor disorders prevention with personal pelvic floor exercises
Study: NCT04123990

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iron status testing
Description: Iron status testing
Study: NCT01368809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 ml at induction 1-2 ml boluses as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
Study: NCT02817230

Intervention type: DRUG
Intervention: Statin
Study: NCT02719431

Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin

Intervention type: DRUG
Group type: OTHER
Intervention: K-877
Study: NCT03443128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: During each course, patients will be treated with vinorelbine (25mg/m2/week on weeks 1-3). After 1 course(4 weeks) of vinorelbine, response will be evaluated by simple assessment: clinical symptoms, signs, B ultrasound, chest X-ray, peripheral blood test and bone marrow smear(if needed). After 2 courses, response will be evaluatedy by simple assessment, CT and FDG-PET. The CR/CRu was defined by anatomic tumour shrinkage more than 75% after 2 courses based on CT with negative PET assessment, with negative bone marrow PCR(if needed) and without CNS involvement. Patients who achieved a CR/CRu after two courses either will proceed to stem cell transplantation (SCT) or will receive additional courses of therapy while awaiting SCT. Response was re-evaluated at the end of every 2 courses. Patients with progressive disease at any time during treatment will be removed from protocol therapy.
Study: NCT03341572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5,10 and 15cmH2O positive end expiratory pressure
Description: every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5,10 and 15cmH2O positive end expiratory pressure
Description: every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points
Study: NCT00904293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype-guided dose determination
Description: Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-genotype guided warfarin dosing
Description: Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
Study: NCT04582942

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEG
Description: Patients began to drink 1 L of PEG at 8:00 PM on the day before colonoscopy at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took the remaining 2 L of PEG 4-6 hours before colonoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG+lactulose
Description: On the day before colonoscopy , Patients took 45 mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took 45 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
Study: NCT01657097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02615821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Contrasting
Description: n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Contrasting
Description: n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Contrasting
Description: n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
Study: NCT01219049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine
Description: 1000 mg / day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine
Description: 2000 mg / day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily
Study: NCT02855671

Intervention type: DEVICE
Intervention: Infrared thermal imaging
Description: Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)

Intervention type: DEVICE
Intervention: Infrared thermal imaging
Description: Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)

Intervention type: DEVICE
Intervention: Infrared thermal imaging
Description: Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)
Study: NCT02198092

Intervention type: OTHER
Intervention: Epi proColon Testing
Description: Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.~For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C.

Intervention type: OTHER
Intervention: Epi proColon Testing
Description: Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.~For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C.

Intervention type: OTHER
Intervention: Epi proColon Testing
Description: Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.~For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C.

Intervention type: OTHER
Intervention: Epi proColon Testing
Description: Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.~For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C.
Study: NCT00146081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Management
Description: Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Management
Description: Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Management
Description: Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Management
Description: Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.
Study: NCT02183922

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: microencapsulated conjugated linoleic acid
Description: The microencapsulated conjugated linoleic acid received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: microencapsulated fish oil
Description: The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: light fruit jam
Description: The placebo group received light fruit jam (15 g/day) during 12 weeks.
Study: NCT03149614

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spine Mobilizations
Description: Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vertebral Resonant Oscillation
Description: The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens ; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992.